Quick Comparison
| Pinealamin | Testagen | |
|---|---|---|
| Half-Life | Variable across the peptide mixture — minutes to hours; effects attributed to gene expression changes | Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure |
| Typical Dosage | Oral (enteric-coated capsule): 10 mg once or twice daily for 10-30 day cycles, often combined with bedtime dosing for sleep applications. Cycles typically repeated 2-3 times per year. Standard Khavinson cycling rather than continuous dosing. | Oral (capsule): 100-200 mg once daily for 10-30 day cycles, repeated 2-3 times per year. Subcutaneous injection: 1-5 mg per dose, alternate days for 10-20 day cycles. Cycling protocol consistent with the Khavinson family. |
| Administration | Oral enteric-coated capsule (cycled) | Oral capsule or subcutaneous injection (cycled) |
| Research Papers | 0 papers | 2 papers |
| Categories |
Mechanism of Action
Pinealamin
Pinealamin is a low-molecular-weight peptide extract derived from the pineal glands of young cattle, processed to isolate short peptides (typically under 10 kDa) with proposed bioregulatory activity on pineal gland function. Unlike defined Khavinson tripeptides such as pinealon (Glu-Asp-Arg), pinealamin is a complex mixture of multiple peptide species, and its biological activity is attributed to the combined effect of these peptides rather than a single active component.
The proposed mechanism follows the Khavinson bioregulator framework: tissue-derived short peptides preferentially target the same tissue type from which they were extracted, binding to gene promoter regions and modulating expression of genes involved in pineal-specific functions. For pinealamin, this is hypothesised to include regulation of melatonin biosynthesis enzymes (notably AANAT and HIOMT), serotonin-to-melatonin conversion pathways, and the broader hypothalamic-pituitary-pineal axis that governs circadian rhythm.
Clinical positioning is primarily for age-related decline in melatonin secretion and associated sleep disorders in older adults — Russian observational studies have reported improvements in subjective sleep quality and measured melatonin output following pinealamin courses in middle-aged and elderly subjects. As with all Khavinson cytamins, the efficacy and mechanism evidence base sits almost entirely within Russian research traditions and has not been replicated in Western randomised controlled trials. The animal-derived sourcing also raises quality and safety considerations that vary significantly between suppliers, and pharmacopoeial standards for pinealamin do not exist outside Russian regulatory frameworks.
Testagen
Testagen is a short Khavinson tetrapeptide (Lys-Glu-Asp-Gly) positioned as the male reproductive and prostate tissue bioregulator within the wider Khavinson peptide family. The proposed mechanism is consistent with the family-wide model: short peptides interact with gene promoter regions in target tissue cells, modulating tissue-specific gene expression patterns to support normal cellular function and counteract age-related decline.
Proposed targets include genes regulating prostate epithelial proliferation and differentiation, androgen receptor signalling sensitivity, and local immune function within prostatic and testicular tissue. Russian research groups have reported testagen-induced improvements in indices of urinary and sexual function in elderly men with age-related prostatic and testicular decline, and animal studies have suggested effects on testicular function markers and prostate gland histology.
As with all Khavinson bioregulators, the published efficacy evidence sits almost entirely within Russian gerontology research traditions and has not been replicated in independent Western randomised controlled trials. Importantly, testagen is not validated for the prevention or treatment of prostate cancer or benign prostatic hyperplasia, and its safety in men with hormone-sensitive cancers has not been established. Use should not displace evidence-based urology care, and users with prostate concerns should consult a urologist rather than relying on bioregulator protocols.
Risks & Safety
Pinealamin
Common
generally well tolerated in Russian observational studies; occasional reports of mild GI discomfort.
Serious
animal-derived raw material introduces theoretical infectious risk (manufacturing controls vary by source); limited Western clinical safety data.
Rare
allergic reactions to bovine peptide content. Quality control varies significantly between suppliers.
Testagen
Common
generally reported as well tolerated.
Serious
very limited Western clinical data; not validated for prostate cancer prevention or treatment, and any effect on hormone-sensitive tissues remains uncharacterised in rigorous trials.
Rare
allergic reactions. Should not replace evidence-based urology care.
Full Profiles
Pinealamin →
A peptide complex extracted from the pineal glands of young animals (typically calves), developed by Vladimir Khavinson's group as a tissue-specific bioregulator for the pineal gland. Promoted for sleep regulation, melatonin support, and age-related circadian rhythm decline. A complex mixture of short peptides rather than a single defined molecule, which differentiates it from synthetic Khavinson tripeptides like pinealon.
Testagen →
A Khavinson tetrapeptide (Lys-Glu-Asp-Gly) developed in Russia as a tissue-specific bioregulator targeting prostate and testicular tissue. Promoted for supporting age-related decline in male reproductive and urinary function. Sits in the same Khavinson family as the other tissue-specific cytogens. Western clinical evidence is limited.